Biomarker-driven surrogate endpoints to accelerate clinical development in immuno-oncology
18 Jun 2024
Salon C
Clinical Development
- Can biomarker-driven surrogate endpoints be used to accelerate early clinical trials? What are the challenges to get there?
- How can we identify biomarkers that better capture the mechanism of action and response to I-O agents to be utilized as potential surrogate endpoints?
- What are the considerations and validation studies that necessary to gain confidence in these biomarkers as surrogate endpoints?
- How can we better design clinical trials to incorporate relevant biomarkers and decision-making based on these biomarkers?
Industry Expert
